Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | BLK | P51451 | 1/20 | 0.64 |
| ▸ | BMX | P51813 | 1/20 | 0.64 |
| ▸ | JAK3 | P52333 | 1/20 | 0.64 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948738 | 0.91 | EGFR (0.68) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2947891 | 0.90 | EGFR (0.64) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2941300 | 0.88 | EGFR (0.64) | EGFRERBB2ERBB4 | |
| SCHEMBL2951755 | 0.86 | EGFR (0.71) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2947200 | 0.86 | EGFR (0.62) | EGFRERBB2ERBB4 | |
| SCHEMBL2949644 | 0.86 | EGFR (0.60) | EGFRERBB2SRCERBB4 | |
| SCHEMBL2944553 | 0.85 | EGFR (0.60) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2943431 | 0.83 | EGFR (0.67) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2943432 | 0.83 | EGFR (0.67) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2950314 | 0.83 | EGFR (0.66) | EGFRERBB2FYNSRCERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | claimed |
| US-7754729-B2 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-07-13 | — | — | US | claimed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | claimed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| EP-2045245-B1 | INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF | TIAN JIN HEMAY BIO TECH CO LTD (CN) | 2013-10-23 | — | — | EP | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-7754729-B2 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-07-13 | — | — | US | disclosed |
| US-7754729-B2 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-07-13 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| EP-2045245-A1 | INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | ABL1, MAP3K7, MAP3K5 | EGFR 616/4885ERBB2 199/4885FYN 506/4885 |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885FYN 122/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885FYN 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.